Navigation Links
Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
Date:6/2/2009

CAMBRIDGE, Mass., June 2 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has promoted F. Stephen Laroux, Ph.D., to the new position of director, immunology and inflammatory diseases, effective immediately. Dr. Laroux joined the company as a scientist in 2007. Today, he leads the team of Cequent researchers developing drug candidates using Cequent's proprietary tkRNAi delivery platform against a series of targets thought to be important in gastro-intestinal diseases, such as inflammatory bowel disease (IBD). Dr. Laroux's current study portfolio includes the target associated with Cequent's partnership with Novartis, as well as Cequent's in-house IBD program.

"While we are furthest along with our drug candidate CEQ508, an orally administered tkRNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis) -- our IBD program is actually the company's largest, and Stephen has been critical to our rapid progress over the past 18 months," said Cequent President and CEO, Peter Parker. "We started with fourteen potential therapeutic targets for IBD, including several in our partnership with Novartis. We have finished in vivo testing on candidate treatments against our first four targets, and all have exhibited significant efficacy. This is a testament to the promise of our tkRNAi technology -- but also to Stephen's skills and tenacity in both study design and execution. Thanks to his leadership and hard work we are now positioned to file two IND (investigational new drug) applications with the FDA for IBD therapeutics next year."

Dr. Laroux completed a post-doctoral fellowship at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School where he conducted research focused on innate immune responses to bacteria a
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cequent Names Ted Hibben Chief Business Officer
2. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. AIAA names top ten emerging aerospace technologies of 2009
7. Microbia, Inc. Names Alex Chu as Vice President of Process Development
8. Premier Research Names Hal Ward, R.Ph., PharmD as Executive Director, Global Pharmacovigilance
9. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Hospira Names Brian Meadows Supply Chain Chief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Xencor, Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... appointment of Debra Zack , M.D., Ph.D., ... Lloyd Rowland , senior vice president, chief ... "Debra,s expertise in biologics clinical development and medical ...
(Date:9/2/2014)... Winston-Salem, NC and Rocky Mount, NC (PRWEB) September 02, ... (PMG) announced today the establishment of its 11th clinical ... 1, PMG Research has assumed ownership and operation of ... in Rocky Mount, NC, further expanding PMG’s presence in ... to an additional 130,000 patients. For the patients in ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue: India Solid Waste Management Vehicles ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... governing bodies responsible for complete handling and regulation ... average, around 135,000 MT solid waste is generated ...
(Date:8/31/2014)... Available spectra is similar for all L-series products ... a wide range of plants. The spectra is ... and pending wide spectrum technology. The single chip ... in contrast to growth spectra made from monochromatic ... large variety of differently sized and shaped growing ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:9/1/2014)... decisions of the Nomenclature Section of the XVIII International ... 2011. This meeting is held every six years and ... rules for naming algae, fungi and plants get together ... the organisms they study. This is the primary product ... algae, fungi, and plants, which was published in 2012. ...
(Date:8/31/2014)... fast and accurate tool to diagnose tuberculosis in ... developed test (TAM-TB assay) is the first reliable ... The test features excellent specificity, a similar sensitivity ... a blood test. The promising findings are a ... children, particularly in tuberculosis-endemic regions. , The study ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... WORCESTER, Mass. Orthopedic surgeons are often hamstrung ... bone injuries resulting from trauma, aging or cancer. Conventional ... or brittle ceramics, and cannot readily conform to the ... in addition, they often require metallic fixation devices that ...
... Swiss needle cast epidemic in Douglas-fir forests of the coastal ... over at least the past 100 years, and is probably ... and a warmer climate, new research concludes. Scientists in ... found that this disease, which is affecting hundreds of thousands ...
... the University of Alabama at Birmingham (UAB) have been ... Scholarship and Excellence in Education Foundation. Atbin Doroodchi, ... Biology and Mathematics. He has a 3.95 grade-point average ... Honors Program. Doroodchi is an undergraduate researcher in the ...
Cached Biology News:Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2Forest epidemic is unprecedented phenomenon, still getting worse 2Forest epidemic is unprecedented phenomenon, still getting worse 3Forest epidemic is unprecedented phenomenon, still getting worse 43 UAB students awarded prestigious Goldwater scholarships 2
... Clone/PAD: ZMD.358. Immunogen: Synthetic ... region of human mouse and ... with human and mouse LRP5 ... (positive controls: mouse LRP5-pSEC-tag-transfected 293T ...
MarrowMAX Bone Marrow Medium...
... recognizes murine IRF7 protein, and ... related IRF proteins. Reactivity of ... protein was confirmed by western ... cells transfected with IRF7. Reactivity ...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
Biology Products: